Myriad Genetics Signs Marketing Plans With Pfizer For BRACAnalysis CDx Test

Myriad Genetics, Inc. and Pfizer Inc. signed an agreement to promote Myriad's BRACAnalysis CDx test, currently under US FDA review, as a companion diagnostic for Pfizer's investigational breast cancer drug, talazoparib.

HER2

Myriad Genetics Inc. inked a deal with pharmaceutical giant Pfizer Inc. to promote Myriad's BRACAnalysis CDx test to identify breast cancer patients that would benefit from treatment with talazoparib, Pfizer's investigational poly-ADP ribose polymerase inhibitor drug.

Under the agreement, both companies will remain responsible for marketing their own products, but will collaborate on certain activities to...

More from Deals

More from Business